摘要
目的:研究卡维地洛对胆汁淤积性肝纤维化大鼠肝组织中TLR4表达及其下游信号通路的影响,为卡维地洛治疗肝纤维化提供实验依据。 方法:将50只雄性Sprague Dawley大鼠随机分为5组(每组10只):假手术(SHAM)对照组,胆管结扎(BDL)模型组,低剂量卡维地洛治疗组(0.1mg ・kg-1·d-1),中剂量卡维地洛治疗组(1mg·kg-1·d-1)和高剂量卡维地洛治疗组(10mg·kg-1·d-1)。应用BDL建立大鼠肝纤维化模型。手术后四十八小时,每天两次卡维地洛。术后两周内在无菌条件下同时采集血液和肝脏以进行进一步检测。测量血清中的丙氨酸氨基转移酶(ALT),天冬氨酸氨基转移酶(AST),总胆红素(TBil)和白蛋白(Alb)。 HE和Masson染色用于确定肝纤维化程度。羟脯氨酸测定法用于检测肝脏胶原蛋白的合成。用Western Blot检测TLR4,NF-κBp65和β-arrestin2蛋白的表达。通过实时PCR对TLR4,MyD88,TNF-α和IL-6 mRNA进行定量分析。 结果:与SHAM组相比,BDL组肝损伤明显,炎症因子水平升高,肝纤维化持续发展。卡维地洛治疗组减轻了BDL组的上述变化。随着剂量增加,改善效果增强。此外,与BDL组相比,高剂量卡维地洛组肝脏组织中TLR4,MyD88和NF-κBp65表达的降低以及β-arrestin2表达的升高更为显着。 结论:卡维地洛可通过下调TLR4的表达并抑制其下游信号通路来减少炎症介质的释放,从而在胆汁淤积性肝纤维化中起潜在的治疗作用。
关键词: 卡维地洛,肝纤维化,TLR4,NF-κB,β-arrestin2,SHAM组。
Current Molecular Medicine
Title:Effects of Carvedilol on the Expression of TLR4 and its Downstream Signaling Pathway in the Liver Tissues of Rats with Cholestatic Liver Fibrosis
Volume: 20 Issue: 9
关键词: 卡维地洛,肝纤维化,TLR4,NF-κB,β-arrestin2,SHAM组。
摘要:
Objectives: This study was designed to investigate the effects of carvedilol on the expression of TLR4 and its downstream signaling pathway in the liver tissues of rats with cholestatic liver fibrosis and provide experimental evidence for clinical treatment of liver fibrosis with carvedilol.
Methods: A total of fifty male Sprague Dawley rats were randomly divided into five groups (10 rats per group): sham operation (SHAM) control group, bile duct ligation (BDL) model group, low-dose carvedilol treatment group (0.1mg·kg-1·d-1), medium-dose carvedilol treatment group (1mg·kg-1·d-1), and high-dose carvedilol treatment group (10mg·kg-1·d-1). Rat hepatic fibrosis model was established by applying BDL. Forty-eight hours after the operation, carvedilol was administered twice a day. The blood and liver were simultaneously collected under the aseptic condition for further detection in two weeks after the operation. The alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBil) and albumin (Alb) in serum were measured. HE and Masson staining were used to determine hepatic fibrosis degree. Hydroxyproline assay was employed to detect liver collagen synthesis. Western Blot was used to measure the expression of TLR4, NF-κB p65 and β-arrestin2 protein. Quantitative analysis of TLR4, MyD88, TNF-α and IL-6 mRNA was performed by Realtime-PCR.
Results: Compared with the SHAM group, the BDL group showed obvious liver injury, increased levels of inflammatory factors, and continued progression of liver fibrosis. The above changes in the BDL group were alleviated in the carvedilol treatment groups. The improvement effects augmented as dosages increased. In addition, compared with the BDL group, the reduction of the expressions of TLR4, MyD88 and NF-κB p65 in liver tissues and the increase of the expression of β -arrestin2 in the high-dose carvedilol group were more significant.
Conclusion: Carvedilol can reduce the release of inflammatory mediators by downregulating TLR4 expression and inhibiting its downstream signaling pathway, thus playing a potential therapeutic role in cholestatic liver fibrosis.
Export Options
About this article
Cite this article as:
Effects of Carvedilol on the Expression of TLR4 and its Downstream Signaling Pathway in the Liver Tissues of Rats with Cholestatic Liver Fibrosis, Current Molecular Medicine 2020; 20 (9) . https://dx.doi.org/10.2174/1566524020666200220130705
DOI https://dx.doi.org/10.2174/1566524020666200220130705 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mini-Review: Nucleus-Targeted Ribonucleases As Antitumor Drugs
Current Medicinal Chemistry Immunotoxins Constructed with Ribosome-Inactivating Proteins and their Enhancers: A Lethal Cocktail with Tumor Specific Efficacy
Current Pharmaceutical Design Modulation of Inducible Nitric Oxide Synthase Activation by Immuno-suppressive Drugs
Current Drug Metabolism Self-Renewal Versus Differentiation in Hematopoietic Stem and Progenitor Cells: A Focus on Asymmetric Cell Divisions
Current Stem Cell Research & Therapy Angiotensin II, Cell Proliferation and Angiogenesis Regulator: Biologic and Therapeutic Implications in Cancer
Current Vascular Pharmacology Imatinib Reduces the Vasculogenic Potential of Plastic Tumor Cells
Current Angiogenesis (Discontinued) Editorial: [Hot Topic: Epigenetics in Arthritis]
Current Rheumatology Reviews Prevention and treatment of atherosclerosis with flaxseed -derived compound secoisolariciresinol diglucoside
Current Pharmaceutical Design Stem Cell-Based Approaches for Intervertebral Disc Regeneration
Current Stem Cell Research & Therapy A New Role for Zn(II) Aminopeptidases: Antigenic Peptide Generation and Destruction
Current Pharmaceutical Design Tyrosyl-DNA Phosphodiesterase as a Target for Anticancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Piper Sarmentosum: A New Hope for the Treatment of Osteoporosis
Current Drug Targets Ceramide Kinase and the Ceramide-1-Phosphate/cPLA2α Interaction as a Therapeutic Target
Current Drug Targets Editorial [Exploring Neural-Immune System Interactions]
Current Immunology Reviews (Discontinued) Chemical and Structural Diversity of siRNA Molecules
Current Topics in Medicinal Chemistry Atorvastatin Inhibits Advanced Glycation End Products (AGE)-Induced C-Reactive Expression in Hepatoma Cells by Suppressing Reactive Oxygen Species Generation
Vascular Disease Prevention (Discontinued) Statins and Portal Hypertension: A New Pharmacological Challenge
Current Vascular Pharmacology Biomedical Consequences of Alcohol Use Disorders in the HIV-Infected Host
Current HIV Research Common Features of the Metabolic Syndrome and Nonalcoholic Fatty Liver Disease
Reviews on Recent Clinical Trials C/EBPα Regulates FOXC1 to Modulate Tumor Growth by Interacting with PPARγ in Hepatocellular Carcinoma
Current Cancer Drug Targets